Shifting Paradigms in Minimally Invasive Surgery: Applications of Transanal Natural Orifice Transluminal Endoscopic Surgery in Colorectal Surgery

Grace Clara Lee, MD1  Patricia Sylla, MD1

1 Division of Gastrointestinal Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts


Address for correspondence  Patricia Sylla, MD, FACS, FASCRS, Division of Colon and Rectal Surgery, Department of Surgery, Mount Sinai Hospital, 5 East 98th Street, Box 1259, New York, NY 10029 (e-mail: patricia.sylla@mountsinai.org).

Abstract

Since the advent of laparoscopy, minimally invasive techniques such as single port laparoscopy, robotics, endoscopically assisted laparoscopy, and transanal endoscopic surgery continue to revolutionize the field of colorectal surgery. Transanal natural orifice transluminal endoscopic surgery (NOTES) represents a further paradigm shift by combining the advantages of these earlier techniques to reduce the size and number of abdominal incisions and potentially optimize rectal dissection, especially with respect to performance of an oncologically adequate total mesorectal excision (TME) for rectal cancer. Since the first experimental report of transanal rectosigmoid resection in 2007, the potential impact of transanal NOTES in colorectal surgery has been extensively investigated in experimental models and recently transitioned to clinical application. There have been 14 clinical trials of transanal TME (taTME) for rectal cancer that have demonstrated the feasibility and preliminary oncologic safety of this approach in carefully selected patients, with results comparable to outcomes after laparoscopic and open TME, including cumulative intraoperative and postoperative complication rates of 5.5 and 35.5%, respectively, 97.3% rate of complete or near-complete specimens, and 93.6% rate of negative margins. Transanal NOTES has also been safely applied to proctectomy and colectomy for benign indications. The consensus among published series suggests that taTME is most safely performed with transabdominal assistance by surgeons experienced with laparoscopic TME, transanal endoscopic surgery, and sphincter-preserving techniques including intersphincteric resection. Future applications of transanal NOTES may include evolution to a pure endoscopic transanal approach for TME, colectomy, and sentinel lymph node biopsy for rectal cancer, with a potential role for robotic assistance.

Keywords

► transanal
► NOTES
► TME
► mesorectal excision
► proctectomy

Though adoption of the surgical principles of total mesorectal excision (TME) in combination with chemoradiation for locally advanced disease has continued to improve local control and survival rates of resectable rectal cancer, radical resection continues to be associated with high morbidity and mortality.1,2 Standard multiport and robotic-assisted laparoscopy, although oncologically safe and associated with shorter length of hospital stay (LOS) than open resections, have not had a measurable impact on the incidence of postoperative complications, sexual and urinary dysfunction,
or quality of life. In addition, widespread adoption of laparoscopic techniques in colorectal surgery has been severely limited by the technical complexity and steep learning curve required to gain expertise in minimally invasive pelvic resections. In an effort to harness the advantages of a minimally invasive approach to benefit patients with colorectal pathology, transanal natural orifice transluminal endoscopic surgery (NOTES) has been explored, with promising preliminary results, particularly when used for rectal cancer. Here, we review the history of NOTES, evolution of minimally invasive and transanal approaches applied to colorectal diseases, results of transanal NOTES proctectomy clinical trials for both malignant and benign indications, current indications for NOTES proctectomy, and future applications of NOTES.

**History of Natural Orifice Transluminal Endoscopic Surgery**

The first clinical report of transgastric appendectomy performed using a flexible endoscope by Reddy and Rao in 2004 ignited worldwide interest in NOTES as a method of extending flexible endoscopy into the realm of minimally invasive intra-abdominal surgery. Over the subsequent few years, NOTES was intensely explored in animal models with the hope of significantly reducing access trauma by operating through a natural orifice instead of the abdominal or thoracic wall. Theoretical advantages of this approach included decreased postoperative pain, faster postoperative recovery, decreased postoperative complications, including wound infections and incisional hernias, as well as improved cosmesis.

After experimental evidence in animal models demonstrated the feasibility and safety of peritoneal access via transoral, transanal, transurethral, and transvaginal routes, NOTES cautiously entered clinical practice. While transgastric approaches were initially most popular, the risks of creating a gastrostomy solely for access purposes were deemed prohibitively high. Transvaginal NOTES procedures quickly surpassed all other transluminal access routes with thousands of transvaginal cholecystectomies performed to date using either rigid or flexible instrumentation with excellent safety profile and patient satisfaction scores. Transanal and transcolonic NOTES were adopted more slowly because of initial concerns about risk of infection and reliable colorectal incisional closure. Extensive evidence in swine survival models, however, demonstrated the safety of transcolonic NOTES peritoneoscopy and other intra-abdominal procedures, as long as adequate closure of the colotomy was achieved.

Colorectal resection ensued as the most logical application of transanal NOTES. Beyond the theoretical benefits common to all NOTES procedures, transanal NOTES had the distinct advantage of creating the viscerotomy within the diseased target organ and incorporating it into the colorectal anastomosis. Several endoscopic prototypes designed to achieve safe transluminal access, dissection, and endoscopic closure were explored without successful transition to clinical trial, highlighting the obstacles faced by NOTES with performing complex endoscopic procedures with maladapted instrumentation.

In this setting, the report by Whiteford et al in 2007, describing rectosigmoid resection in three human cadavers using a purely transanal approach with transanal endoscopic microsurgery (TEM), was a turning point in the evolution of transanal NOTES. It highlighted the potential of performing complex colorectal dissection using existing transanal endoscopic platforms, thus enabling experimental and then clinical trials using this innovative approach.

**Evolution of Minimally Invasive Approaches to Rectal Surgery**

The development of transanal NOTES approach for rectal resection comes in the context of efforts to minimize the morbidity and mortality of open rectal surgery. Three decades following its original description by Heald, TME has become the gold standard for curative rectal cancer resection. However, it continues to be associated with a 1 to 6% mortality rate as well as high perioperative morbidity, including anastomotic leak (0–21%), wound complications (0–47%), and hernia formation (0–11%), as well as functional disorders, including defecatory (0.5–37%), urinary (5–14%), and sexual dysfunction (33–36%).

Relative to open TME, laparoscopic TME is associated with decreased postoperative pain, decreased LOS, and faster return of bowel function, with similar oncologic outcomes based on large randomized controlled trials, including the CLASSIC and COLOR II trials. However, laparoscopic TME has not been widely adopted because of the difficulty of the pelvic dissection, long operative time, steep learning curve, and minimal impact of the laparoscopic approach on functional outcomes. Regardless of the specific reasons for the lack of wider adoption, it is estimated that well under 30% of the rectal cancer resections in the United States are performed using laparoscopy, without significant improvement over the past decade, and persistently high conversion rates (15–30%). Single-port laparoscopy for colon resections has not been shown to provide advantages over traditional laparoscopy and has been minimally investigated for rectal resections because of technical difficulty. Preliminary data from large series on robotic TME suggest equivalent perioperative and oncologic outcomes relative to laparoscopic TME, but with decreased conversion rates to open surgery. However, robotic surgery is associated with significantly longer operative times and higher procedural costs, potentially problematic in this environment of health-care cost reduction. Furthermore, laparoscopic and robotic TME still require a sizeable abdominal incision for specimen removal, minimizing their wound-related benefits over open TME.

In addition to NOTES, natural orifice specimen extraction (NOSE) has gained increasing popularity, with many groups reporting successful transvaginal and transanal removal of colorectal resection specimens. Many of these procedures have been performed for benign indications, such as rectal prolapse and diverticulitis; however, there have also been several studies employing this technique for colorectal cancer resections. Park et al compared laparoscopic right colectomy with transvaginal versus transabdominal extraction (n = 68) and found decreased postoperative pain and LOS associated...
with transvaginal removal, though wound infections and intra-abdominal abscesses were not significantly decreased.\textsuperscript{60} Leung et al (n = 70) conducted a randomized trial of laparoscopic left colectomy with transanal versus transabdominal extraction, finding decreased postoperative pain (p = 0.017) and wound infections (p = 0.005) with transanal NOSE.\textsuperscript{61} A large retrospective comparison (n = 432) by Liang et al of laparoscopic TME for rectal cancer with transanal or transabdominal specimen extraction found no difference in intraoperative complications (p = 0.69), postoperative complications (p = 0.59), LOS (p = 0.83), or 2-year local recurrence rates (p = 0.15).\textsuperscript{62,63} Thus, preliminary results show NOSE to be feasible for colorectal cancer resection, with possible advantages including reduction in postoperative pain, LOS, and wound infection rates.

**Evolution of Transanal Approaches to Rectal Surgery**

Alongside these minimally invasive transabdominal approaches to colorectal surgery, transanal techniques for the removal of rectal lesions have been developed. Over the last three decades, TEM has provided excellent endoscopic local control for proximal rectal lesions through improved visualization and full thickness resection, resulting in decreased fragmentation of specimens relative to conventional transanal excision.\textsuperscript{64–66} In addition, TEM has been associated with exceedingly low mortality and morbidity relative to radical proctectomy.\textsuperscript{67,68} More recently, transanal minimally invasive surgery (TAMIS), a newer technique that utilizes flexible and disposable transanal endoscopic platforms and accommodates traditional laparoscopic instruments, has accelerated the popularity of transanal endoscopic surgery worldwide.\textsuperscript{59–72} Inherent limitations of TEM and TAMIS apply to all local excision techniques, namely the lack of mesorectal clearance with prohibitively high recurrence rates when used to resect T2 and more advanced rectal tumors. As a result, TEM and TAMIS are only indicated for resection of benign indications.\textsuperscript{85} For low-risk features, as local recurrence rates for those lesions after TEM are similar to rates after TME,\textsuperscript{73–81} Transanal NOTES expands the conventional indications of TEM and TAMIS by taking advantage of the exposure and dissection of the perirectal and mesorectal planes, transanal NOTES may optimize the quality of rectal resections while minimizing the morbidity of these procedures.

**Clinical Trials of Transanal Natural Orifice Transluminal Endoscopic Surgery**

Numerous porcine survival and human cadaver trials have confirmed the safety and feasibility of a transanal NOTES approach to colorectal resection.\textsuperscript{19,83–90} In the largest cadaver study (n = 32), adequate TME was achieved in every cadaver and, when comparing different transanal approaches, the laparoscopic-assisted technique was found to be particularly important in minimizing organ injury and maximizing specimen length,\textsuperscript{97} leading to the subsequent use of laparoscopic assistance in many clinical trials.

Currently, transanal NOTES has been most thoroughly investigated for TME for rectal cancer. However, several reports have described both pure and laparoscopic-assisted transanal NOTES approaches to perform colorectal resections for benign indications.

**Transanal Natural Orifice Transluminal Endoscopic Surgery Proctectomy and Colectomy for Benign Disease**

Lacy et al were the first to report a successful laparoscopic-assisted transanal NOTES total colectomy in a 36-year-old
Fig. 1  Laparoscopic-assisted taTME in an obese male patient with a T2N0 low rectal cancer. The rectum is sutured closed below the tumor with a purse string located just above the dentate line (A) and the transanal endoscopic platform is inserted. After CO2 insufflation of the rectum, the rectal mucosa is scored circumferentially with monopolar cautery (B). Full-thickness rectal and mesorectal dissection is completed posteriorly along the presacral space (C), laterally, and anteriorly along the rectoprostatic plane (D) until the peritoneal reflection is reached and the abdominal cavity entered anteriorly (E). Rectal and mesorectal dissection is completed using a combined abdominal and transanal approach, and the specimen is transected transanally if feasible. Stapled coloanal anastomosis is performed (F) followed by a protective diverting loop ileostomy (G). A complete TME is achieved with negative margins and 25 negative lymph nodes (H). taTME, transanal total mesorectal excision; TME, total mesorectal excision.
man with medically refractory ulcerative colitis. Total operative time was 240 minutes and there were no surgical complications.

Fuchs et al performed laparoscopic-assisted transanal colon resections in 15 patients with additional rectopexy in 11 of the 15 patients for benign indications (full-thickness rectal prolapse, internal rectal intussusception with pelvic obstruction, recurrent sigmoid diverticulitis, and severe slow-transit constipation). There were no intraoperative complications except for one conversion to full laparoscopy with a minilaparotomy to remove the bulky specimen in a patient with diverticulitis. Mean operative time was 131 minutes. There were two postoperative complications (postoperative ileus that resolved with conservative management and intra-abdominal bleeding that required a transfusion but no other intervention). At 6-month follow-up, the median Gastrointestinal Quality of Life Index increased significantly ($p < 0.05$) and no patient reported any functional complaints.

Liyanage et al report a series of 12 patients who underwent transanal completion proctectomy for inflammatory bowel disease, rectal adenomas, or radiation proctitis. All procedures were performed purely transanally except in two patients. Mean rectal stump length was 17.8 cm. Median LOS was 5.5 days. There were seven postoperative complications (five delayed wound healing, one temporary incarcera-
ton of a parastomal hernia, and one colocutaneous fistula to the perineum in the patient with radiation proctitis, which required operative intervention).

Wolthuis et al describe a series of 14 transanal rectal excisions, laparoscopically assisted in 11 of the cases, for benign and malignant indications. Among the nine pa-
tients with benign disease (inflammatory bowel disease, fistula, adenoma, fecal incontinence, and anastomotic complications), ISR with coloanal anastomosis was performed in six patients and proctectomy with end colostomy was performed in the remaining three patients. Mean operating time was 146 minutes. Two patients required conversion to open surgery because of extensive adhesions. Mean LOS was 7.6 days and minor complications occurred in 4 of the 14 patients.

Thus, these early trials suggest that transanal NOTES is feasible for proctectomy and colectomy in carefully selected patients with benign disease, and is most commonly and safely performed with laparoscopic assistance.

Transanal Natural Orifice Transluminal Endoscopic Surgery Total Mesorectal Excision for Rectal Cancer

With regard to rectal cancer resection, there have been an increasing number of transanal NOTES TME (taTME) cases performed since the first clinical report of laparoscopic-assisted taTME in a 76-year-old woman with rectal cancer. Thus far, 14 clinical series have been reported from groups in the United States, Asia, and Europe, involving a total of 110 patients (Table 1). Sixty-seven percent of the patients were male, mean patient age was 61.5 years, mean body mass index (BMI) was 25.8 kg/m², and 80.6% of the patients received neoadjuvant therapy.

In general, most series selected patients based on tumor-specific criteria including low- and mid-rectal resectable tumors (staged by pelvic magnetic resonance imaging [MRI] and/or endorectal ultrasound), with no evidence of metastases on computed tomographic (CT) scan, and excluded patients with BMI $> 35$ kg/m² and previous extensive abdominal or pelvic surgery. By contrast, two series intentionally selected patients with anatomical features predictive of difficult rectal dissection (narrow pelvis, BMI $> 30$ kg/m², and large prostate). Rouanet et al also selected patients with T4 and recurrent tumors, including 25 patients (75%) with predicted circumferential resection margins $\leq 1$ mm based on MRI and 3 patients (10%) with known metastases before surgery. Overall, in all 14 series, 44.1% of the tumors were located in the lower rectum (< 5 cm from the AV), 52.7% were in the middle (5–10 cm from the AV), and 3.2% were high (> 10 cm from the AV). Of the 43 patients for whom preoperative nodal status was reported, 41.9% had positive nodes. On final pathology, 37.7% of the patients had positive nodes.

Mean operative time was 265.6 minutes and mean estimated blood loss was 138.2 mL. Most of the series utilized a hybrid NOTES technique; 89 cases were laparoscopic assisted, 6 were robotic assisted, 3 were open assisted, and 12 were unassisted, purely transanal NOTES. Despite the majority of these trials being transabdominally assisted, most of the rectal dissection was performed transanally, hence their classification as transanal NOTES, as opposed to NOSE. The rectum was occluded transanally with a purse-string suture before making the enterotomy in 92.7% of the patients. In 69.1% of the patients, the splenic flexure was partially or fully mobilized. Seventy-seven percent of the patients received a diverting ileostomy. All groups extracted the specimen transanally, except Dumont et al who utilized the future ileostomy site and Atallah et al who used a Pfannenstiel incision.

The overall intraoperative complication rate across all 14 clinical series of taTME was 5.5%, with 2 conversions to open surgery, 2 urethral injuries, 1 possible air embolism, and 1 episode of pneumatisis of the small bowel mesentery. Rouanet et al, who published the series of high-risk patients, reported five of the six intraoperative events, explaining that the complications occurred early in the surgeons’ learning curve and in patients with large, fixed tumors. The rate of conversion to open surgery was 1.8%, which compares favorably to published conversion rates after laparoscopic TME of 0 to 34%.

The cumulative postoperative complication rate across all series of taTME was 35.5%, comparable to published morbidity rates of 21 to 44% and 24 to 51% after laparoscopic and open TME, respectively. Morbidity included 12 infectious (10.9%) and 5 anastomotic (4.5%) complications. Six patients experienced urinary dysfunction (5.5%), likely because of pelvic nerve injury and comparable to reported rates after laparoscopic (up to 20%) and open (5–14%) TME. Mean LOS after taTME was 9.5 days, no patient died within 30 days of surgery, and no patient developed incisional hernias during follow-up.
### Table 1 Patient characteristics of published clinical series on transanal TME

<table>
<thead>
<tr>
<th>Series</th>
<th>N</th>
<th>Age (y)</th>
<th>Gender</th>
<th>BMI (kg/m²)</th>
<th>Tumor location (cm)</th>
<th>Neoadjuvant CRT</th>
<th>Operative technique</th>
<th>Transanal platform</th>
<th>Operating time (min)</th>
<th>Final TNM stage (n)</th>
<th>Number of lymph nodes collected</th>
<th>TME quality</th>
<th>Margins (n) Distal margin² Circumferential margin²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sylla et al 2010</td>
<td>1</td>
<td>76</td>
<td>F</td>
<td>20</td>
<td>6 cm from AV</td>
<td>Yes</td>
<td>LA</td>
<td>Rigid metal (TEO; Karl Storz Endoscopy-America, Inc., Il Segundo, CA)</td>
<td>270</td>
<td>ypT1N0</td>
<td>23</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Chen et al 2010</td>
<td>1</td>
<td>47</td>
<td>M</td>
<td>22</td>
<td>5 cm from AV</td>
<td>Yes</td>
<td>LA</td>
<td>Custom-made</td>
<td>290</td>
<td>pT3N2</td>
<td>25</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Tuch et al 2011</td>
<td>1</td>
<td>45</td>
<td>F</td>
<td>20</td>
<td>3 cm from DC</td>
<td>No</td>
<td>LA</td>
<td>Rigid single port (Endo-secure, Apside Medical; La Talaudiere, France)</td>
<td>300</td>
<td>pT1mN0</td>
<td>15</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Zorcon et al 2012</td>
<td>2</td>
<td>54, 73</td>
<td>M (1), F (1)</td>
<td>NR</td>
<td>6, 8 cm from AV</td>
<td>No</td>
<td>LA</td>
<td>Colonoscope, single port (Triport; Olympus America, Southborough, MA)</td>
<td>390, 410</td>
<td>pT3N1M0 (2)</td>
<td>11, 12</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Dumont et al 2013</td>
<td>4</td>
<td>66.8 (60–76)</td>
<td>M (4)</td>
<td>23.4 (22.4–24.5)</td>
<td>5.3 (4–7) cm from AV</td>
<td>Yes</td>
<td>LA</td>
<td>Single port (Gelpoint; Applied Medical, Rancho Santa Margarita, CA)</td>
<td>360 (270–460)</td>
<td>NR</td>
<td>16 (8–22)</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Lacy et al 2013</td>
<td>3</td>
<td>73 (71–75)</td>
<td>M (1), F (2)</td>
<td>21.7 (16–25)</td>
<td>9.7 (9–10) cm from AV</td>
<td>Yes (2), No (1)</td>
<td>LA</td>
<td>Single port (Gelpoint; Applied Medical)</td>
<td>143 (125–155)</td>
<td>pT1N0M0 (1), pT3N0M0 (2)</td>
<td>NR</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Velhuus et al 2011</td>
<td>5</td>
<td>69.4 (61–79)</td>
<td>M (3), F (2)</td>
<td>NR</td>
<td>6 (5–8) cm from AV</td>
<td>Yes</td>
<td>LA</td>
<td>Single port (365, Covidien, Mansfield, MA)</td>
<td>178.2 (160–194)</td>
<td>pT0N0M0 (1), pT1N0M0 (1), pT1N1M0 (1)</td>
<td>13.4 (11–17)</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Lacy et al 2013</td>
<td>20</td>
<td>65 (44–77)</td>
<td>M (17), F (9)</td>
<td>25.3 (19–33)</td>
<td>6.3 (2–15) cm from AV</td>
<td>Yes (14), No (6)</td>
<td>LA</td>
<td>Single port (Gelpoint; Applied Medical)</td>
<td>234.7 (150–325)</td>
<td>High-grade dysplasia (2), stage I (4), stage II (7), stage III (6), stage IV (1)</td>
<td>15.9 ± 4.3</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Rouanet et al 2013</td>
<td>30</td>
<td>65 (43–82)</td>
<td>M (30)</td>
<td>26.0 (21.0–32.4)</td>
<td>&lt; 5 cm from AV (n = 20), 5 to 10 cm from AV (n = 10)</td>
<td>Yes (29), No (1)</td>
<td>LA</td>
<td>Rigid metal (TEO; Karl Storz Endoscopy-America, Inc.)</td>
<td>304 (120–432)</td>
<td>pT1 (1), pT2 (5), pT3 (18), pT4 (3), pN0 (14), pN1 (13), pN2 (3)</td>
<td>13 (8–32)</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Sylla et al 2013</td>
<td>5</td>
<td>48.6 (36–63)</td>
<td>M (3), F (2)</td>
<td>25.7 (22–28)</td>
<td>5.7 (4–10) cm from AV</td>
<td>Yes (2), No (3)</td>
<td>LA</td>
<td>Rigid metal (TEO; Karl Storz Endoscopy-America, Inc.)</td>
<td>274.6 (214–423)</td>
<td>pT0N0M0 (1), pT1N0 (2), pT2N1 (1), ypT2N0 (2)</td>
<td>33 (16–53)</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Lenoy et al 2013</td>
<td>1</td>
<td>56</td>
<td>F</td>
<td>NR</td>
<td>Mid-third of rectum</td>
<td>No</td>
<td>P</td>
<td>Rigid metal (TEO; Karl Storz Endoscopy-America, Inc.)</td>
<td>190</td>
<td>Adenoma with low-grade dysplasia</td>
<td>16</td>
<td>Complete</td>
<td>NR</td>
</tr>
<tr>
<td>Zhang et al 2013</td>
<td>1</td>
<td>48</td>
<td>F</td>
<td>20</td>
<td>7 cm from AV</td>
<td>NR</td>
<td>P</td>
<td>Single port (PHO; Ethicon Endo-surgery, Inc., Cincinnati, Ohio)</td>
<td>300</td>
<td>pT3N1M0</td>
<td>12</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Atallah et al 2013</td>
<td>20</td>
<td>57 (36–73)</td>
<td>M (14), F (6)</td>
<td>24 (18–41)</td>
<td>5 (1–9) cm from AV</td>
<td>Yes (17), No (3)</td>
<td>LA (11), RA (6), OA (3)</td>
<td>Single port (Gelpoint; Applied Medical) and Single port (365, Covidien USA)</td>
<td>243 (140–495)</td>
<td>ypT0N0 (5), ypT0N2 (1), ypT2N0 (3), ypT3N0 (4), ypT3N1 (2), ypT3N2 (1), ypT4N0 (1)</td>
<td>22.5 (5–51)</td>
<td>Complete (11), near complete (6), incomplete (2)</td>
<td>Negative (11), positive (2)</td>
</tr>
<tr>
<td>Cheuillard et al 2014</td>
<td>16</td>
<td>57.7 (41–81)</td>
<td>M (6), F (10)</td>
<td>27.9 (21–38)</td>
<td>Mid- or low-rectal tumors</td>
<td>NR</td>
<td>LA (6), P (10)</td>
<td>Single port (365, Covidien USA)</td>
<td>265 (155–440)</td>
<td>pT1N0 (1), pT1N0 (1), pT2N0 (3), pT2N1 (1), pT3N0 (3), pT3N1 (3), pT3N2 (1), pT4N0 (1)</td>
<td>17 (12–81)</td>
<td>Complete</td>
<td>Negative</td>
</tr>
<tr>
<td>Overall</td>
<td>110</td>
<td>61.3 (34–82)</td>
<td>M (74), F (36)</td>
<td>25.8 (16–41)</td>
<td>&lt; 5 cm from AV (n = 41), 5 to 10 cm from AV (n = 49), &gt; 10 cm from AV (n = 19)</td>
<td>Yes (75), No (18)</td>
<td>LA (89), RA (6), OA (3), P (12)</td>
<td>–</td>
<td>265.6 (120–495)</td>
<td>pT0 (10), pT1 (8), pT2 (20), pT3 (42), pT4 (65), N0 (66), N1–2 (40)</td>
<td>17.9 (8–81)</td>
<td>Complete (101), near complete (6), incomplete (2)</td>
<td>Negative (10), positive (6)</td>
</tr>
</tbody>
</table>

Abbreviations: AV, anal verge; CRT, chemoradiation therapy; DL, dentate line; F, female; LA, laparoscopic assisted; M, male; NR, not reported; OA, open-assisted; P, pure NOTES; RA, robotic assisted; TME, total mesorectal excision; TNM, tumor-node-metastasis.

¹Mean as mean (range) for series with n ≥ 1.

²Data reported as mean ± standard error of the mean.
## Table 2 Postoperative outcomes of published clinical series on transanal TME

<table>
<thead>
<tr>
<th>Series</th>
<th>Length of stay (d)*</th>
<th>Intraoperative complications (n)</th>
<th>Postoperative complications (n)</th>
<th>Oncologic outcomes (n)</th>
<th>Functional outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sylla et al 2010[2]</td>
<td>5</td>
<td>None</td>
<td>None</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Chen et al 2010[3]</td>
<td>NR</td>
<td>None</td>
<td>None</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Zorrón et al 2012[5]</td>
<td>6</td>
<td>None</td>
<td>Feet paresthesia related to intraoperative positioning (1)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Dumont et al 2012[6]</td>
<td>13 (10–21)</td>
<td>None</td>
<td>Anastomotic fistula (treated with antibiotics, drainage) (1)</td>
<td>No recurrence at 43-month follow-up</td>
<td>No severe incontinence (median Wexner score 5) at 3-month follow-up</td>
</tr>
<tr>
<td>Lacy et al 2013[7]</td>
<td>4.7 (4–5)</td>
<td>None</td>
<td>Dehydration requiring readmission (1)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Velthuis et al 2013[8]</td>
<td>NR</td>
<td>Pneumatosis of small bowel mesentery (1)</td>
<td>Pneumonia and ileus (1), and presacral abscess (1)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Lacy et al 2013[9]</td>
<td>6.5 ± 3.1b</td>
<td>None</td>
<td>Urinary retention (2), ileus (1), and dehydration (1)</td>
<td>No recurrence at 30-day follow-up</td>
<td>NR</td>
</tr>
<tr>
<td>Rouanet et al 2013[10]</td>
<td>14 (9–25)</td>
<td>Conversion to open (2), urethral injury (2), and air embolism (1)</td>
<td>Peritonitis (2), septic shock (1), bowel obstruction (2), anastomotic leakage (1), and urinary dysfunction (2)</td>
<td>No recurrence (13), treated for recurrence (12), cancer-related deaths (4) at 21-month follow-up</td>
<td>40% continent, 15% incontinent to liquids, 35% to gas, 25% with stool fragmentation (median Wexner score 11) at 12-month follow-up (n = 12)</td>
</tr>
<tr>
<td>Sylla et al 2013[11]</td>
<td>5.2 (4–10)</td>
<td>None</td>
<td>Urinary dysfunction (2), and ileus (1)</td>
<td>No recurrence at 54-month follow-up</td>
<td>NR</td>
</tr>
<tr>
<td>Leroy et al 2013[12]</td>
<td>NR</td>
<td>None</td>
<td>Small pelvic hematoma (treated with CT-guided drainage) (1)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Zhang et al 2013[13]</td>
<td>NR</td>
<td>None</td>
<td>None</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Atallah et al 2013[14]</td>
<td>4.5 (3–24)</td>
<td>None</td>
<td>Wound infection (2), pelvic abscess (4), prolonged ileus (4), pneumonia (1), acute renal failure (1), anastomotic leak requiring reoperation (1), and peri-anastomotic fluid collection (2)</td>
<td>No local recurrence at 6-month follow-up. One patient with distant metastases found 9 months after surgery.</td>
<td>&quot;Most&quot; patients with mild fecal incontinence (&lt; 1 accident/d) 8 weeks after ileostomy closure. One patient with lifestyle-limiting incontinence (Wexner score 16)</td>
</tr>
<tr>
<td>Chouillard et al 2014[15]</td>
<td>10 (4–29)</td>
<td>None</td>
<td>Small bowel obstruction requiring reoperation (2), and pelvic abscess requiring reoperation (1)</td>
<td>No recurrence at 9-month follow-up</td>
<td>NR</td>
</tr>
<tr>
<td>Overall</td>
<td>9.5 (3–29)</td>
<td>6 intraoperative complications</td>
<td>39 postoperative complications</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: CT, computed tomography; NR, not reported; TME, total mesorectal excision.

*Given as mean (range) for series with n ≥ 3.

bData reported as mean ± standard error of the mean.

*Functional outcomes were reported in the 14 patients who underwent diverting ileostomy closure.
Oncologic results are similarly promising, with R0 resections achieved in 93.6% of the patients. Six patients had positive margins: four were high-risk patients with aggressive tumors reported by Rouanet et al and two had margins of 1 mm reported by Atallah et al.\textsuperscript{102,108} This rate of positive margins (5.5%) is consistent with historical rates published in the literature for laparoscopic (1.2–16%) and open (1.3–16%) TME.\textsuperscript{1,36–38,40,42,113} Mean lymph node harvest was 17.9 nodes, which compares favorably to published rates of laparoscopic and open TME.\textsuperscript{1,37,40,42,113} Only two specimens were deemed incomplete; Atallah et al explained that these two specimens contained defects of \( \geq 5 \text{ mm} \) in the mesorectal envelopes but margins were negative and the patients did not recur during follow-up.\textsuperscript{102}

Lacy et al, Dumont et al, Sylla et al, and Chouillard et al reported no tumor recurrence after follow-up periods of 30 days, 4.3 months, 5.4 months, and 9 months, respectively.\textsuperscript{43,82,84,104} Atallah et al found no local recurrence after median follow-up of 6 months; however, one patient developed distant metastases.\textsuperscript{102} Though that patient’s final pathology was ypT3N0 with complete TME specimen and negative margins and negative nodes, liver metastases were found 9 months after surgery and the patient required curative liver resection. In the high-risk patient cohort of Rouanet et al, 13 had no recurrence (43%), 12 were treated for recurrence (40%), and 4 died of cancer-related causes (13%) during their 21-month follow-up period.\textsuperscript{108} Disease-free survival rates were 93.3% and 88.9% and overall survival rates were 96.6% and 80.5% at 12- and 24-month follow-up, respectively. Even in this patient population selected for high-risk tumors, these overall survival rates are similar to those after laparoscopic (85.8–90.7%) and 77.1–80.4% at 12 and 24 months, respectively) and open (80.5–92.7% and 69.5–83.3%) TME.\textsuperscript{35,42}

Preliminary results of functional outcomes after taTME demonstrate similar postoperative sphincter function when compared with laparoscopic or open TME. Rouanet et al, who performed partial ISR and used a rigid transanal platform, demonstrated a median Wexner score of 11 at 12-month follow-up, at which time 40% of the patients who underwent ileostomy closure were fully continent, 15% were incontinent to liquids, 35% were incontinent to gas, and 25% had stool incontinence.\textsuperscript{108} This is comparable to published results of TME with ISR, which report median Wexner scores of 10.8 to 11.\textsuperscript{118–120} Dumont et al and Atallah et al both used flexible transanal platforms and externalized the specimen transabdominally; Dumont et al’s cohort had a median Wexner score of 5 at 3 months after ileostomy reversal, while “most” of Atallah et al’s cohort had mild fecal incontinence (< 1 accident per day) at 8 weeks after ileostomy takedown.\textsuperscript{43,102} One patient reported by Atallah et al had lifestyle-limiting incontinence, with a Wexner score of 16. These results are similar to functional outcomes after TME with low coloanal anastomoses (median Wexner score of 6.9).\textsuperscript{118}

Thus, these clinical series demonstrate taTME to be feasible and oncologically safe. However, these preliminary results must be interpreted carefully, as they are based on aggregating data from a few studies with small cohorts, variable patient characteristics, different surgical techniques and equipment, and short follow-up periods. The morbidity, oncologic outcomes, and functional outcomes of transanal TME must be clarified by large trials with long-term follow-up before widespread adoption of transanal NOTES. Future trials may also elucidate any differences in postoperative pain, wound complications, and recovery time after NOTES versus conventional surgical approaches.

**Current Indications for Transanal Natural Orifice Transluminal Endoscopic Surgery Proctectomy and Total Mesorectal Excision**

Based on the current published experience with transanal NOTES proctectomy and TME, these complex procedures should be performed by surgeons with significant experience in laparoscopic or robotic TME, TEM or TAMIS, and ISR.\textsuperscript{111} Like with many minimally invasive techniques, a steep learning curve must be overcome to master transanal NOTES. In the largest cadaver series of transanal TME, Telem et al demonstrated decreased operative time (\( p = 0.13 \)) and increased specimen length (\( p = 0.001 \)) after the first five cadavers.\textsuperscript{97} This data suggests that procedural training with fresh human cadavers should be considered as the optimal training model for this approach. Alternatively, Buscaglia et al recently found that transanal NOTES sigmoidectomy training using an endoscopy-simulation model decreased operative time by 42% and may also be effective in gaining proficiency.\textsuperscript{122}

Because of the limitations of currently available transanal instruments, NOTES colorectal procedures should be performed using a hybrid fashion, with transabdominal assistance. The same cadaver study by Telem et al compared three different approaches: transanal alone, transanal with transgastric assistance, and transanal with laparoscopic assistance.\textsuperscript{97} They found decreased operative time with the laparoscopic-assisted technique, as well as decreased complications, though the latter was not statistically significant. Laparoscopic assistance is helpful for mobilization of the splenic flexure, retraction of the colon during transanal rectal dissection, and identification of the ureters and pelvic nerves. While there have been 12 cases of unassisted transanal TME,\textsuperscript{107,111} platforms and instruments tailored to complex transanal surgery must be developed before pure transanal NOTES procedures can become commonplace.

The initial clinical experiences of transanal TME also demonstrate the importance of careful patient selection, particularly while many surgeons are early in the learning curve, and while larger studies on this technique continue to investigate long-term functional and oncologic outcomes of this approach. Currently, transanal NOTES procedures should only be performed in patients with benign disease or premalignant or resectable malignant tumors, preferably located in the low- or mid-rectum.\textsuperscript{17} These patients should have no history of extensive abdominal or pelvic surgery.
Ideally, with increased surgeon expertise, tTME may be safely and consistently performed in patients likely to benefit most from a transanal approach. These are patients with characteristics that predict difficult transabdominal rectal dissections, including a narrow or deep pelvis, male gender, obesity, large prostate, low rectal tumor (< 5 cm from AV), and previous neoadjuvant radiation. Transanal TME may be particularly appropriate for these patients because of enhanced visualization and technically easier rectal and mesorectal dissection, which has the potential to improve the quality of the specimen and reduce the incidence of positive margins. Some groups, notably Rouanet et al and Dumont et al, have already begun investigating taTME in this subset of patients, with early results demonstrating equivalent morbidity and oncologic outcomes to previously published data from laparoscopic and open TME. Nevertheless, taTME should not be performed on these high-risk patients until the surgical team has gained clinical expertise with NOTES techniques and until the long-term oncologic outcomes of these procedures are reported.

**Future Applications of Transanal Natural Orifice Transluminal Endoscopic Surgery**

Improvements in transanal platforms and specialized instruments have the potential to revolutionize applications of transanal NOTES. Pure, unassisted NOTES procedures will likely become easier to perform and may maximize the theoretical benefits of natural orifice surgery, namely decreased postoperative pain, wound complications, and recovery time. There have been 12 reported cases of pure transanal NOTES TME so far, 2 case reports and 10 patients who were part of a larger series. In all cases, the specimen was intact and > 11 nodes were collected. There were no intraoperative complications and three postoperative complications (a small pelvic hematoma treated with CT-guided drainage, a small bowel obstruction requiring reoperation, and a pelvic abscess requiring reoperation). Pure transanal NOTES has also been successfully reported for pull-through colectomy in six pediatric patients with long-segment intestinal aganglionosis, suggesting that pure NOTES may be used for indications beyond the simple removal of isolated lesions.

Development of longer, more flexible scopes and instruments may also enable transanal NOTES procedures for more proximal colorectal lesions. Very few groups have pursued transanal colon resections because of the difficulty of dissection using currently available tools, though laparoscopic-assisted transanal colectomy for benign disease has been shown to be safe and feasible by Lacy et al and Fuchs et al. In addition, Hall et al reported an excision of a rectal scar and successful transanal intraperitoneal creation of the colorectal anastomosis using a TEM platform, TEM instruments, and PDS suture, with no laparoscopic assistance. Though the resection margins were already closely approximated because of the small size of the scar and were thus under minimal tension, this case demonstrates the feasibility of suturing a colorectal anastomosis entirely intraperitoneally using a transanal platform, suggesting that more proximal transanal colorectal resections may be possible without the need to externalize the margins to perform a handsewn anastomosis. Nevertheless, the EURO-NOTES working group’s 2012 recommendations state that transanal NOTES should currently only be utilized if the colotomy can be incorporated into the specimen or anastomosis, essentially restricting it to left-sided colon and rectal procedures.

Another potential future application of NOTES is to biopsy sentinel lymph nodes (SLN) for rectal cancer. Currently, there is much debate over how to determine which patients with rectal cancer require radical resection and which will have similar oncologic outcomes after local excision. Radiologic staging has poor sensitivity for nodal spread, and local excision with transanal endoscopic surgery does not enable assessment of nodal status. Transanal NOTES offers the possibility of obtaining more accurate staging by removing the tumor and then sampling SLN through the colotomy site, particularly appropriate given that 98% of the positive nodes are located in the laterodorsal mesorectum within 5 cm of the tumor. Transanal NOTES segmental sigmoid resection and SLN extraction was demonstrated to be feasible in a porcine model that used submucosal injection of methylene blue dye to locate the SLN. Arezzo reported a small human series (n = 3) in which indocyanine green was instilled in the submucosa around the rectal tumor, the tumor was removed, the fat dissected, and the SLN successfully removed, all via transanal NOTES. There were no complications specific to nodal dissection and removal, and the mesorectal fascia was preserved, maintaining oncologic integrity. Nevertheless, the utility of SLN biopsy in colorectal cancer is still under debate, as results are widely variable, with sensitivity rates ranging from 25 to 100% and false negative rates ranging from 0 to 75%.

Another area of innovation with transanal NOTES is the incorporation of robotic technology. Robotics has been reported to improve visualization using 3-dimensional optical technology, enable ambidextrous movements, decrease tremor, and improve dexterity, particularly in confined spaces. Cadaver models have proven the feasibility of robotic TAMIS, and an initial clinical series (n = 16) by Hompes et al of robotic TAMIS for rectal lesions has demonstrated promising results. There has also been a cadaver series of laparoscopic-assisted robotic transanal TME, in which complete TME specimens were obtained in all four cadavers. Atallah et al reported the only clinical case thus far of robotic-assisted robotic transanal TME in a 51-year-old woman with a preoperatively staged T3N1 rectal tumor located 4 cm from the AV. The operative time was 381 minutes, there were no complications, negative margins were achieved, and the specimen quality was near-complete. These preliminary results demonstrate the safety and feasibility of robotic transanal NOTES; however, more trials are needed to elucidate the benefits and costs of adding robotic technology to the standard transanal endoscopic approach.

**Conclusion**

Transanal NOTES represents a paradigm shift in minimally invasive colorectal surgery, combining the benefits of TEM...
and TAMIS, ISR, and NOSE to minimize access trauma and optimize the quality and ease of rectal dissection. The transanal NOTES approach to TME for rectal cancer and proctocolectomy for benign disease has shown encouraging preliminary results; however, there is a need for larger trials to better characterize outcomes, advantages, disadvantages, and cost before widespread adoption. Currently, transanal NOTES procedures should only be performed in carefully selected patients with transabdominal assistance by surgeons experienced with laparoscopic TME, TEM or TAMIS, and ISR.

References
28 Maggiori L, Panis Y. Is it time for a paradigm shift? “laparoscopy is now the best approach for rectal cancer”? Transl Gastrointest Cancer 2014;3(1):1–3
Applications of Transanal NOTES in Colorectal Surgery

Lee, Sylla

191


55 Ooi BS, Quah HM, Fu CW, Eu KW. Laparoscopic high anterior resection with natural orifice specimen extraction (NOSE) for early rectal cancer. Tech Coloproctol 2009;13(1):61–64


60 Park JS, Choi GS, Kim HJ, Park SY, Jun SH. Natural orifice specimen extraction versus conventional laparoscopically assisted right hemicolectomy. Br J Surg 2011;98(5):710–715


71 Atallah SB, Albert MR. Transanal minimally invasive surgery (TAMIS) versus transanal endoscopic microsurgery (TEM): is one better than the other? Surg Endosc 2013;27(12):4750–4751

Applications of Transanal NOTES in Colorectal Surgery

Lee, Sylla


81 You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database Ann Surg 2007;245(5):726–733


